Chemokines in granulomatous lung inflammation

Stephen W. Chensue, Akihiro Matsukawa, Cory M. Hogaboam, Steven L. Kunkel

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The clinical manifestations of pulmonary granulomatous diseases are usually the consequence of long-term leukocyte elicitation and activation, resulting in chronic tissue inflammation and lung injury (1). Most interstitial granulomatous diseases in the lung are difficult to treat, requiring therapies that may seriously compromise the immunologic and physiologic integrity of the patient. Historically, the therapeutic approach to the treatment of infectious granulomatous disease has been to target the known infectious agent, while treatment of idiopathic granulomatous diseases has usually targeted immune/inflammatory cell function. Once the pulmonary disease is diagnosed, antimicrobial agents are used to treat the former, while immunosuppressive agents are usually used to treat the latter disease states (2,3). Unfortunately, the clinical management of these diseases does not necessarily ablate the subsequent pathology, which is observed in certain patients. This is especially true in difficult clinical cases, such as drug-resistant mycobacterial diseases or progressive sarcoidosis refractory to corticosteroids (2). Thus, the limited therapeutic options, which are available to effectively manage patients with granulomatous lung disease, may reflect the limited understanding of the mechanisms underlying these chronic diseases.

Original languageEnglish
Title of host publicationChemokines in the Lung
PublisherCRC Press
Pages221-237
Number of pages17
ISBN (Electronic)9780824747442
ISBN (Print)9780824708580
Publication statusPublished - Jan 1 2003
Externally publishedYes

Fingerprint

Chemokines
Pneumonia
Lung Diseases
Therapeutics
Lung Injury
Immunosuppressive Agents
Sarcoidosis
Disease Management
Anti-Infective Agents
Communicable Diseases
Adrenal Cortex Hormones
Leukocytes
Chronic Disease
Pathology
Inflammation
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chensue, S. W., Matsukawa, A., Hogaboam, C. M., & Kunkel, S. L. (2003). Chemokines in granulomatous lung inflammation. In Chemokines in the Lung (pp. 221-237). CRC Press.

Chemokines in granulomatous lung inflammation. / Chensue, Stephen W.; Matsukawa, Akihiro; Hogaboam, Cory M.; Kunkel, Steven L.

Chemokines in the Lung. CRC Press, 2003. p. 221-237.

Research output: Chapter in Book/Report/Conference proceedingChapter

Chensue, SW, Matsukawa, A, Hogaboam, CM & Kunkel, SL 2003, Chemokines in granulomatous lung inflammation. in Chemokines in the Lung. CRC Press, pp. 221-237.
Chensue SW, Matsukawa A, Hogaboam CM, Kunkel SL. Chemokines in granulomatous lung inflammation. In Chemokines in the Lung. CRC Press. 2003. p. 221-237
Chensue, Stephen W. ; Matsukawa, Akihiro ; Hogaboam, Cory M. ; Kunkel, Steven L. / Chemokines in granulomatous lung inflammation. Chemokines in the Lung. CRC Press, 2003. pp. 221-237
@inbook{811b24f7e74f41da8a6bf77f5cc90f2a,
title = "Chemokines in granulomatous lung inflammation",
abstract = "The clinical manifestations of pulmonary granulomatous diseases are usually the consequence of long-term leukocyte elicitation and activation, resulting in chronic tissue inflammation and lung injury (1). Most interstitial granulomatous diseases in the lung are difficult to treat, requiring therapies that may seriously compromise the immunologic and physiologic integrity of the patient. Historically, the therapeutic approach to the treatment of infectious granulomatous disease has been to target the known infectious agent, while treatment of idiopathic granulomatous diseases has usually targeted immune/inflammatory cell function. Once the pulmonary disease is diagnosed, antimicrobial agents are used to treat the former, while immunosuppressive agents are usually used to treat the latter disease states (2,3). Unfortunately, the clinical management of these diseases does not necessarily ablate the subsequent pathology, which is observed in certain patients. This is especially true in difficult clinical cases, such as drug-resistant mycobacterial diseases or progressive sarcoidosis refractory to corticosteroids (2). Thus, the limited therapeutic options, which are available to effectively manage patients with granulomatous lung disease, may reflect the limited understanding of the mechanisms underlying these chronic diseases.",
author = "Chensue, {Stephen W.} and Akihiro Matsukawa and Hogaboam, {Cory M.} and Kunkel, {Steven L.}",
year = "2003",
month = "1",
day = "1",
language = "English",
isbn = "9780824708580",
pages = "221--237",
booktitle = "Chemokines in the Lung",
publisher = "CRC Press",

}

TY - CHAP

T1 - Chemokines in granulomatous lung inflammation

AU - Chensue, Stephen W.

AU - Matsukawa, Akihiro

AU - Hogaboam, Cory M.

AU - Kunkel, Steven L.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - The clinical manifestations of pulmonary granulomatous diseases are usually the consequence of long-term leukocyte elicitation and activation, resulting in chronic tissue inflammation and lung injury (1). Most interstitial granulomatous diseases in the lung are difficult to treat, requiring therapies that may seriously compromise the immunologic and physiologic integrity of the patient. Historically, the therapeutic approach to the treatment of infectious granulomatous disease has been to target the known infectious agent, while treatment of idiopathic granulomatous diseases has usually targeted immune/inflammatory cell function. Once the pulmonary disease is diagnosed, antimicrobial agents are used to treat the former, while immunosuppressive agents are usually used to treat the latter disease states (2,3). Unfortunately, the clinical management of these diseases does not necessarily ablate the subsequent pathology, which is observed in certain patients. This is especially true in difficult clinical cases, such as drug-resistant mycobacterial diseases or progressive sarcoidosis refractory to corticosteroids (2). Thus, the limited therapeutic options, which are available to effectively manage patients with granulomatous lung disease, may reflect the limited understanding of the mechanisms underlying these chronic diseases.

AB - The clinical manifestations of pulmonary granulomatous diseases are usually the consequence of long-term leukocyte elicitation and activation, resulting in chronic tissue inflammation and lung injury (1). Most interstitial granulomatous diseases in the lung are difficult to treat, requiring therapies that may seriously compromise the immunologic and physiologic integrity of the patient. Historically, the therapeutic approach to the treatment of infectious granulomatous disease has been to target the known infectious agent, while treatment of idiopathic granulomatous diseases has usually targeted immune/inflammatory cell function. Once the pulmonary disease is diagnosed, antimicrobial agents are used to treat the former, while immunosuppressive agents are usually used to treat the latter disease states (2,3). Unfortunately, the clinical management of these diseases does not necessarily ablate the subsequent pathology, which is observed in certain patients. This is especially true in difficult clinical cases, such as drug-resistant mycobacterial diseases or progressive sarcoidosis refractory to corticosteroids (2). Thus, the limited therapeutic options, which are available to effectively manage patients with granulomatous lung disease, may reflect the limited understanding of the mechanisms underlying these chronic diseases.

UR - http://www.scopus.com/inward/record.url?scp=85056913046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056913046&partnerID=8YFLogxK

M3 - Chapter

SN - 9780824708580

SP - 221

EP - 237

BT - Chemokines in the Lung

PB - CRC Press

ER -